AHA 2023: Novel Imaging/Hemodynamic Based Right Ventricular Phenotypes in Patients With Pulmonary Hypertension

Janowski, A., Visovatti, S., Benza, R., Vanderpool, R. “Novel Imaging/Hemodynamic Based Right Ventricular Phenotypes in Patients With Pulmonary Hypertension”. Introduction:  Right ventricular function and ventricular dynamics associate with outcomes in pulmonary hypertension (PH). Measures of RV strain describe ventricular mechanics but are not included in RV function assessments. This study aimed to develop novel RV […]

AHA 2023: Comparison of Pulmonary Arterial Risk Assessment Tools using a harmonized FDA dataset

Fauvel, C., Lin, S., Correa-Jaque, P., Everett, A., Perer, A., Liu, Y., Kanwar, M., Vanderpool, R., Kraisangka, J., Benza, R. “Comparison of Pulmonary Arterial Risk Assessment Tools using a harmonized FDA dataset”. Introduction:  One-year mortality risk for a pulmonary arterial hypertension (PAH) patient is the most substantial. Accordingly, the initial risk stratification should be the […]

AHA 2023: Improvement of Pulmonary Arterial Hypertension risk assessment model using cardiac magnetic resonance imaging variables

Correa-Jaque, P., Lin, Y., Lin, S., Liu, Y., Fauvel, C., Vanderpool, R., Kanwar, M., Kraisangka, J., Perer, A., Everett, A., Alabed, S., Swift, A., Kiely, D., Benza, R. “Improvement of Pulmonary Arterial Hypertension risk assessment model using cardiac magnetic resonance imaging variables”. Introduction PAH is a deadly disease without cure. Formalized risk stratification allows therapeutic […]

Article in CHEST: Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy? Insight From the AMBITION Trial

Fauvel, C., Liu, Y., Correa-Jaque, P., Kanwar, M., Vizza, C. D., Lin, S., & Benza, R. L.  Background Based on results of the Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial, upfront combination therapy is recommended for treatment-naive patients with low-risk pulmonary arterial hypertension (PAH). However, conflicting data exist whether adopting this treatment […]

AHA 2022: Identification of Novel Right Ventricular Function Phenotypes in Pulmonary Arterial Hypertension Using Unbiased K-Means Clustering.

Vanderpool, R., Janowski, A., Fauvel, C., Liu, Z., Lin, S., Correa-Jaque, P., Webb, A., Kanwar, M., Kraisangka, J., Mathur, P., Perer, A., Everett, A., Visovatti, S., and Benza, R.L. “Identification of Novel Right Ventricular Function Phenotypes in Pulmonary Arterial Hypertension Using Unbiased K-Means Clustering” Introduction: Survival in pulmonary arterial hypertension (PAH) is associated with right ventricular […]

Presentation at CHEST Annual Meeting 2022: Comparison Between Pulmonary Arterial Hypertension (PAH) Risk Assessment Methods, Including Pulmonary Hypertension Outcome Risks Assessment (PHORA) 

Fauvel, C., Liu, Z., Lin, S., Correa-Jaque, P., Webb, A., Vanderpool, R., Kanwar, M., Kraisangka, J., Mathur, P., Perer, A., Everett, A., & Benza, R. L.  “Comparison Between Pulmonary Arterial Hypertension (PAH) Risk Assessment Methods, Including Pulmonary Hypertension Outcome Risks Assessment (PHORA)” PURPOSE: Risk assessment is critical to predict survival and then guide therapeutic management for pulmonary […]

Poster at ERS International Congress 2022: Pulmonary Arterial Hypertension risk assessment model using Bayesian Network Analysis

Fauvel, C., Liu, Z., Lin, S., Correa-Jaque, P., Webb, A., Vanderpool, & Benza, R. L. “Pulmonary Arterial Hypertension risk assessment model using Bayesian Network Analysis” BACKGROUND. Usual pulmonary arterial hypertension (PAH) risk assessment (i.e., used to predict survival) models are based on statistical analysis which do not consider the relationship between variables, assuming their linear association with […]

Poster at PVRI Congress 2022: Comparison between PAH risk assessment methods including PHORA

Fauvel, C., Liu, Z., Lin, S., Correa-Jaque, P., Webb, A., Vanderpool, R., Kanwar, M., Kraisangka, J., Mathur, P., Perer, A., Everett, A., & Benza, R. L. “Comparison between PAH risk assessment methods including PHORA”. BACKGROUND. Risk assessment is critical to predict survival and then guide therapeutic management for pulmonary arterial hypertension (PAH) patients. Several risk […]

Poster at PHA 2022 Conference: Pulmonary Arterial Hypertension Risk Assessment model using Random Forrest and Bayesian Network

Liu, Z., Fauvel, C., Lin, S., Correa-Jaque, P., Webb, A., Vanderpool, R., Kanwar, M., Kraisangka, J., Mathur, P., Perer, A., Everett, A., & Benza, R. L. “Pulmonary Arterial Hypertension Risk Assessment model using Random Forrest and Bayesian Network”. Background and rationale: Existing risk assessment models in pulmonary arterial hypertension (PAH) are powerful in predicating survival. […]

Poster at PHA 2022 Conference: Pulmonary Arterial Hypertension risk assessment genomic model using Bayesian Network

Fauvel, C., Webb, A., Liu, Z., Lin, S., Correa-Jaque, P., & Benza, R. L. “Pulmonary Arterial Hypertension risk assessment genomic model using Bayesian Network”. BACKGROUND AND RATIONALE. Accurate risk assessment is essential to making individualized treatment decision in pulmonary arterial hypertension (PAH) patients. Yet, existing probabilistic risk assessment models are insufficient since they did not […]